Leerink Remains Cautious on Ionis Pharmaceuticals (IONS) Following Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
May 26, 2016 7:30 AM EDTCARLSBAD, Calif., May 26, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today provided an update on the IONIS-TTRRx program. Ionis is currently evaluating IONIS-TTRRx in an ongoing Phase 3 study, NEURO-TTR, in patients with transthyretin (TTR) familial amyloid polyneuropathy.  Dr. Merrill Benson is also evaluating IONIS-TTRRx in an investigator-initiated Phase 2 open-label study in patients with TTR-related amyloid cardiomyopathy.
GSK, which has an... More
